A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects.

Yiming ChengYing YeAllison GaudyAtalanta GhoshYongjun XueAlice WangSimon ZhouYan Li

Published in: Clinical pharmacology : advances and applications (2023)

In summary, 1 mg single oral dose of iberdomide was generally well-tolerated. HI (mild, moderate or severe) had no clinically relevant impact on iberdomide PK and therefore, no dose adjustment is warranted.

Keyphrases

open label
high intensity
early onset
clinical trial
squamous cell carcinoma
randomized controlled trial
drug induced
phase iii
phase ii study